Dendritic cells derived from multiple myeloma patients efficiently internalize different classes of myeloma protein

Experimental Hematology

Volumn 29, Issue 1, 2001, Pages 85-92

  Butch, Anthony W ^a   Kelly, Kathleen A ^a   Munshi, Nikhil C ^b  

^a UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Antigen processing; Dendritic cells; Immunotherapy; Maturation; Multiple myeloma

Indexed keywords

CANCER VACCINE; FLUORESCEIN ISOTHIOCYANATE; PARAPROTEIN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN PRESENTATION; ARTICLE; CELL MATURATION; CLINICAL ARTICLE; DENDRITIC CELL; ENDOCYTOSIS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOTHERAPY; MULTIPLE MYELOMA; PRIORITY JOURNAL;

ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL DIFFERENTIATION; CELLS, CULTURED; CHLOROQUINE; DENDRITIC CELLS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HUMANS; HYDROGEN-ION CONCENTRATION; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN KAPPA-CHAINS; INTERLEUKIN-4; MULTIPLE MYELOMA; MYELOMA PROTEINS; ORGANELLES; PINOCYTOSIS; RECOMBINANT PROTEINS;

EID: 0035166483     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(00)00619-6     Document Type: Article

References (33)

1. Dendritic cells and the control of immunity
2. Origin, maturation and antigen presenting function of dendritic cells
3. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment; downregulation by cytokines and bacterial products
4. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells
5. Mechanisms of antigen uptake for presentation
6. Dendritic cell biology and the application of dendritic cells to the immunotherapy of multiple myeloma
7. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma-a feasibility study
8. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma-long-term results of a clinical trial
9. Dendritic cell-based immunotherapy of prostate cancer
10. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
11. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors
12. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor
13. Dendritic cell-based idiotype vaccination in post transplant multiple myeloma
14. Efficacy of idiotype-pulsed autologous dendritic cells for treatment of advanced refractory multiple myeloma
15. Idiotype protein-pulsed dendritic cell vaccination in multiple myeloma
16. Generation of anti-idiotype immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma
17. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells; immunological and clinical aspects
18. Comparable engraftment kinetics following peripheral blood stem cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma
19. Proliferating dendritic cell progenitors in human blood
20. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood
21. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability
22. Human dendritic cells handling of binding, uptake and degradation of free and IgG-immune complexed dinitrophenylated human serum albumin in vitro
23. Macrophage colony-stimulating factor (rM-CSF) stimulates pinocytosis in bone marrow-derived macrophages
24. Distinct endocytic pathways in epidermal growth factor-stimulated human carcinoma A431 cells
25. Intracellular routes and selective retention of antigens in mildly acidic cathepsin D/lysosome-associated membrane protein-1/MHC class II-positive vesicles in immature dendritic cells
26. Generation of virtually pure and potentially proliferating dendritic cells from non-CD34 apheresis cells from patients with multiple myeloma
27. Dendritic cells generated from the blood of patients with multiple myeloma are phenotypically and functionally identical to those similarly produced from healthy donors
28. + cell-depleted mobilized peripheral blood can serve as a source of potent dendritic cells
29. Dendritic cells as immunotherapy for multiple myeloma
30. M-CSF-induced macropinocytosis increases solute endocytosis but not receptor-mediated endocytosis in mouse macrophages
31. Inhibition of the lysosomal pathway of protein degradation in isolated rat hepatocytes by ammonia, methylamine, chloroquine and leupeptin
32. Stimulation of cytotoxic T cells against idiotype immunoglobulin of malignant lymphoma with protein-pulsed or idiotype-transduced dendritic cells
33. The density of peptides displayed by dendritic cells affects immune responses to human tyrosinase and gp100 in HLA-A2 transgenic mice